Skip to main content
    P

    Protagonist Therapeutics Inc (PTGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $136.55
    +0.27 (+0.20%)

    Market Cap: $8.96B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(21/39)
    Avg Surprise
    +45.51%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$2.60
    Range$0.13 - $3.71
    11 analysts
    EPS Revisions
    2
    0
    7d
    6
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$2.24+16.3%
    60d ago$2.24+16.3%
    30d ago$2.36+10.0%
    7d ago$2.49+4.6%
    Current$2.60
    Revenue Consensus
    $243M
    Range$95M - $292M
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$1.02
    Range$-0.25 - $2.23
    12 analysts
    Revenue Consensus
    $59M
    Range$-54306440 - $106M
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.02---
    Sep 26EST
    		-$2.60---
    Jun 26
    Reported Aug 5
    		$2.29$2.11+8.53%Beat+516.4%
    Mar 26
    Reported May 5
    		$0.05N/A+107.69%Beat+126.3%
    Dec 25
    Reported Feb 25
    		$-0.69$-0.34-102.76%Miss-134.8%
    Sep 25
    Reported Nov 6
    		$-0.62$-0.64+3.13%Beat-14.8%
    Jun 25
    Reported Aug 6
    		$-0.55$-0.52-5.77%Miss-10.0%
    Mar 25
    Reported May 6
    		$-0.19$0.11-272.73%Miss-105.8%
    Dec 24
    Reported Feb 21
    		$1.98$0.25+692.00%Beat+350.0%
    Sep 24
    Reported Nov 7
    		$-0.54$-0.53-1.89%Miss+6.9%
    Jun 24
    Reported Aug 6
    		$-0.50$-0.41-21.95%Miss+26.5%
    Mar 24
    Reported May 7
    		$3.26$1.60+103.75%Beat+586.6%
    Dec 23
    Reported Feb 27
    		$0.44$-0.03+1566.67%Beat+163.8%
    Sep 23
    Reported Nov 2
    		$-0.58$-0.70+17.14%Beat+9.4%
    Jun 23
    Reported Aug 3
    		$-0.68$-0.66-3.03%Miss+19.0%
    Mar 23
    Reported May 4
    		$-0.67$-0.70+4.29%Beat-55.8%
    Dec 22
    Reported Mar 15
    		$-0.69$-0.64-7.81%Miss+10.4%
    Sep 22
    Reported Nov 8
    		$-0.64$-0.85+24.71%Beat+8.6%
    Jun 22
    Reported Aug 4
    		$-0.84$-0.98+14.29%Beat-21.7%
    Mar 22
    Reported May 4
    		$-0.43$-0.60+28.33%Beat+20.4%
    Dec 21
    Reported Feb 28
    		$-0.77$-0.78+1.28%Beat-60.4%
    Sep 21
    Reported Nov 3
    		$-0.70$-0.66-6.06%Miss-233.3%
    Jun 21
    Reported Aug 4
    		$-0.69$-0.53-30.19%Miss-21.1%
    Mar 21
    Reported May 4
    		$-0.54$-0.56+3.57%Beat+25.0%
    Dec 20
    Reported Mar 10
    		$-0.48$-0.48+0.00%Beat+23.8%
    Sep 20
    Reported Nov 4
    		$-0.21N/A+62.50%Beat+65.6%
    Jun 20
    Reported Aug 6
    		$-0.57$-0.58+1.72%Beat+51.7%
    Mar 20
    Reported May 7
    		$-0.72$-0.69-4.35%Miss-24.1%
    Dec 19
    Reported Mar 10
    		$-0.63$-0.70+10.00%Beat-10.5%
    Sep 19
    Reported Nov 6
    		$-0.61$-0.73+16.44%Beat-60.5%
    Jun 19
    Reported Aug 7
    		$-1.18$-0.27-337.04%Miss-187.8%
    Mar 19
    Reported May 8
    		$-0.58$-0.59+1.69%Beat-61.1%
    Dec 18
    Reported Mar 12
    		$-0.57$-0.47-21.28%Miss-280.0%
    Sep 18
    Reported Nov 6
    		$-0.38$-0.33-15.15%Miss-31.0%
    Jun 18
    Reported Aug 7
    		$-0.41$-0.29-41.38%Miss+53.9%
    Mar 18
    Reported May 9
    		$-0.36$-0.24-50.00%Miss+57.1%
    Dec 17
    Reported Mar 7
    		$-0.15N/A+57.14%Beat+77.6%
    Sep 17
    Reported Nov 6
    		$-0.29N/A+52.46%Beat-
    Jun 17
    Reported Aug 8
    		$-0.89$-0.81-9.88%Miss-
    Mar 17
    Reported May 10
    		$-0.84$-0.59-42.37%Miss-
    Dec 16
    Reported Mar 7
    		$-0.67$-0.52-28.85%Miss-

    Key Metrics

    Valuation
    P/E Ratio132.57EV/EBITDA157.00x
    Price/FCF68.95xFCF Yield1.45%
    Profitability
    Profit Margin29.40%Operating Margin74.40%
    ROE11.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio21.71xQuick Ratio21.71x
    Trading Statistics
    Beta1.52Avg Volume846.27K
    52-Week High$160.8152-Week Low$73.08

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$140.01
    SMA 20$140.73
    SMA 50$145.74
    SMA 200$113.56
    EMA 10$139.64
    EMA 20$140.93
    EMA 50$140.76
    EMA 200$117.77

    MACD

    Line: -1.51Signal: -1.23Hist: -0.28

    ADX

    ADX: 15.2+DI: 19.8-DI: 22.1

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down40.0
    PSAR$151.85

    Bollinger Bands

    Upper Band$146.12
    Lower Band$135.34
    %B Position766%(Upper)
    Band Width0.11

    RSI (14-Day)

    Neutral
    40.7

    Momentum Oscillators

    Stoch %K11.3
    Stoch %D30.7
    Williams %R-94.4
    ROC (10d)-1.9%
    Momentum-2.64
    CCI (20d)-141.5
    MFI (14d)47.8

    Volatility Measures

    ATR (14d)$5.45(4.0%)
    StdDev (20d)2.70
    Hist Vol30.6%(Moderate)

    Volume Flow

    VWAP$137.22
    OBV32.5M
    AD Line21.6M
    CMF (20d)-0.147

    Volume Metrics

    Avg Vol (20d)877.6K
    Vol Ratio0.8x
    VWMA (20d)$140.92

    Pivot Points

    R3$145.24
    R2$143.19
    R1$139.73
    Pivot Point$137.68
    S1$134.22
    S2$132.17
    S3$128.71

    Advanced Oscillators

    TSI-10.91
    Ultimate Osc33.2
    KST-46.71

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$213.47M$56.37M$7.44M$4.71M$5.55M$28.32M$170.64M$4.67M$4.17M$254.95M$60.00M$0
    Cost of Revenue$0$0$376,000$0$0$0$604,000$0$0$0$832,000$0
    Gross Profit$213.47M$56.37M$7.44M$4.71M$5.55M$28.32M$170.64M$4.67M$4.17M$254.95M$60.00M$0
    Operating Expenses$54.71M$60.02M$57.79M$51.13M$47.59M$47.63M$43.86M$46.13M$42.96M$48.64M$36.95M$38.33M
    R&D$42.06M$46.74M$46.36M$40.00M$37.04M$35.89M$34.90M$35.97M$33.52M$33.73M$28.90M$30.66M
    SG&A$12.65M$13.28M$11.43M$11.13M$10.55M$11.74M$8.95M$10.16M$9.44M$14.91M$8.05M$7.66M
    Operating Income$158.77M$-3,648,000$-50,355,000$-46,421,000$-42,041,000$-19,310,000$126.78M$-41,453,000$-38,793,000$206.31M$23.05M$-38,326,000
    Interest Income$6.43M$5.88M$6.76M$7.05M$7.41M$7.57M$6.85M$7.68M$7.40M$4.38M$4.24M$4.25M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$165.11M$2.28M$-43,718,000$-39,339,000$-34,599,000$-11,655,000$133.66M$-33,630,000$-31,292,000$210.67M$27.34M$-34,105,000
    Income Tax Expense$2.27M$-1,502,000$666,000$0$172,000$0$1.99M$-420,000$-676,000$3.33M$0$0
    Net Income$162.85M$3.78M$-44,384,000$-39,339,000$-34,771,000$-11,655,000$131.67M$-33,210,000$-30,616,000$207.34M$27.34M$-34,105,000
    EBITDA$158.04M$-4,213,000$-51,439,000$-47,711,000$-43,615,000$-21,278,000$124.17M$-43,919,000$-40,117,000$204.91M$20.24M$-38,536,000
    EBIT$158.69M$-3,595,000$-50,479,000$-46,388,000$-42,005,000$-19,228,000$126.81M$-41,312,000$-38,696,000$206.29M$23.09M$-38,357,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PTGX

    News

    Protagonist Therapeutics (NASDAQ:PTGX) Raised to Strong-Buy at Zacks Research

    Zacks Research has upgraded Protagonist Therapeutics (NASDAQ:PTGX) to a "strong buy" rating, joining other analysts who maintain a bullish outlook with a consensus "buy" rating and an average price target of $154.44....

    MarketBeat•10/16/26•Bullish

    Citi keeps Buy rating for Protagonist Therapeutics stock

    Citi has reiterated its Buy rating for Protagonist Therapeutics (PTGX) stock, setting a price target of USD 182.00. This follows a strong second quarter in 2026 where the company reported USD 213.48 million in revenue...

    ad-hoc-news.de•10/15/26•Bullish

    Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today

    Protagonist Therapeutics (NASDAQ: PTGX) has significantly outperformed the market over the last decade, with an annualized return of 19.88%. An initial investment of $100 in PTGX 10 years ago would now be valued at...

    Benzinga•10/15/26•Somewhat-Bullish

    Protagonist Therapeutics (PTGX) Could Be 21% Undervalued As Royalty Funded Narrative Builds

    Protagonist Therapeutics (PTGX) shares closed at US$138.49, showing positive momentum year-to-date and over the past year. Analysts suggest the stock is 21% undervalued, with a fair value of $174.69...

    Simply Wall Street•10/14/26•Bullish

    Protagonist Therapeutics (NASDAQ:PTGX) Raised to "Strong-Buy" at UBS Group

    UBS Group upgraded Protagonist Therapeutics (NASDAQ:PTGX) to a "strong-buy" rating. This upgrade comes as other analysts, including Leerink Partners and Citigroup...

    MarketBeat•10/14/26•Bullish

    PTGX Valuation and Fair Value

    P/E
    132.6x
    Forward P/E
    36.9x
    EV/EBITDA
    157.0x
    P/FCF
    68.9x
    PEG
    0.0x
    P/B
    10.7x
    See GNG's fair value

    PTGX Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    74.4%
    Net margin
    29.4%
    ROE
    11.0%
    FCF margin
    46.3%
    FCF yield
    1.5%

    PTGX Competitors

    CompanyTicker
    Insulet CorporationPODD
    Cytokinetics IncCYTK
    Qiagen NVQGEN
    Kymera Therapeutics IncKYMR
    10X Genomics IncTXG
    Caris Life Sciences, Inc. Common StockCAI
    Henry Schein IncHSIC
    Hinge Health, Inc.HNGE

    Sector: Healthcare

    PTGX Analyst Ratings

    Consensus
    Buy
    Analysts
    13
    Strong Buy
    3
    Buy
    10
    Hold
    0
    Sell
    0
    Strong Sell
    0

    PTGX Bull Case vs Bear Case

    Bull case

    • PTGX converts 46.3% of revenue into free cash flow.
    • PTGX has a 29.4% net profit margin.
    • PTGX grew quarterly revenue 3749.0% year over year.

    Bear case

    • PTGX trades at 132.6x trailing earnings.

    PTGX Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    53.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $2.60
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    6 up, 3 down

    Frequently Asked Questions About PTGX

    Does PTGX pay dividends?

    Protagonist Therapeutics Inc (PTGX) does not currently pay a regular dividend.

    What is PTGX's P/E ratio?

    Protagonist Therapeutics Inc has a price-to-earnings (P/E) ratio of 132.57.

    What is PTGX's market cap?

    Protagonist Therapeutics Inc (PTGX) has a market capitalization of $8.96B with a current stock price of $136.55.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In